publicações selecionadas
-
artigo académico
- Drug repurposing of dopaminergic drugs to inhibit ataxin-3 aggregation. Biomedicine & Pharmacotherapy. 2023
- Assessment of the gastrointestinal fate of bacterial nanocellulose and its toxicological effects after repeated-dose oral administration. Environmental Science-Nano. 2023
- Case Report: A Novel GNB1 Mutation Causes Global Developmental Delay With Intellectual Disability and Behavioral Disorders. Frontiers in Neurology. 2021
- Mesenchymal stem cell secretome protects against alpha-synuclein-induced neurodegeneration in a Caenorhabditis elegans model of Parkinson's disease. Cytotherapy. 2021
- Polyglutamine spinocerebellar ataxias: emerging therapeutic targets. Expert Opinion on Therapeutic Targets. 2020
- Loss of egli-1, the Caenorhabditis elegans Orthologue of a Downstream Target of SMN, Leads to Abnormalities in Sensorimotor Integration. Molecular Neurobiology. 2020
-
artigo de revista
- Learning the Biochemical Basis of Axonal Guidance: Using Caenorhabditis elegans as a Model. Biomedicines. 2023
- Neurodifferentiation and Neuroprotection Potential of Mesenchymal Stromal Cell-Derived Secretome Produced in Different Dynamic Systems. Biomedicines. 2023
- Microglial Depletion Has No Impact on Disease Progression in a Mouse Model of Machado-Joseph Disease. Cells. 2022
- Profiling Microglia in a Mouse Model of Machado-Joseph Disease. Biomedicines. 2022
- Neurotherapeutic effect of Hyptis spp. leaf extracts in Caenorhabditis elegans models of tauopathy and polyglutamine disease: Role of the glutathione redox cycle. Free Radical Biology and Medicine. 2021
- Data on the effects of Hyptis spp. and Lycium spp. plant extracts in C. elegans models of genetically determined neurodegenerative diseases. Data in Brief. 2020
- GST-4-Dependent Suppression of Neurodegeneration in C. elegans Models of Parkinson's and Machado-Joseph Disease by Rapeseed Pomace Extract Supplementation. Frontiers in Aging Neuroscience. 2019
- From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation. Neurotherapeutics. 2019
- Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease. Molecular Neurobiology. 2019
- Phospholipase D functional ablation has a protective effect in an Alzheimer’s disease Caenorhabditis elegans model. Acta Cytologica. 2018
- Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. Molecular Neurobiology. 2018
- Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3. Movement Disorders. 2018
- Absence of Ataxin-3 Leads to Enhanced Stress Response in C. elegans. Antibiotics. 2011
-
capítulo de livro
-
documento
- Motor coordination and balance ameliorated after treatment of the CMVMJD135 mouse model of Spinocerebellar Ataxia Type 3 with befiradol 2022
- NLX-112 improved the motor coordination and balance in a Mouse Experimental Model of Machado-Joseph Disease 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Disorders 2021
- Disease-modifying therapies for SCA3: lessons from preclinical trials 2019
- Microglial and astrocytic pathology in a mouse model of Machado-Joseph disease 2019
- Anti-aging genetic manipulation in C. elegans impact differentially in Machado-Joseph disease 2019
- The impact of PLD functional ablation in an Alzheimer's disease Caenorhabditis elegans model 2017
- The impact of phospholipase D functional ablation in physiology and in disease models in Caenorhabditis elegans 2017
- Absence of MeCP2 increases postnatal dentate gyrus cell proliferation in a mouse model of Rett syndrome. 2008